Highlights
- The prevalence of multidrug-resistant tuberculosis (MDR-TB) was 36.3% in Amhara National Regional State, Ethiopia indicating that MDR-TB is increasing with time.
- Unlike the high prevalence of MDR-TB, the prevalence of rifampicin and isoniazid heteroresistance was lower at 4.7% and 1.13% respectively.
- Ser531Leu substitution and Ser315Thr1 substitution were the highest gene mutations for rifampicin and isoniazid, respectively.
Summary
Background
Methods
Results
Conclusions
Keywords
1. Introduction
2. Materials and methods
2.1 Study design and sampling technique
2.2 Specimen processing
2.3 LPA interpretation

2.4 Statistical analysis
2.5 Data quality assurance
2.6 Ethical considerations
3. Results
3.1 Multidrug-resistant tuberculosis
Variables | Number | Percentage | |
---|---|---|---|
Sex | Male | 229 | 55.4 |
Female | 184 | 44.6 | |
Age, years | 18 | 22 | 5.3 |
1934 | 211 | 51.1 | |
3545 | 97 | 23.5 | |
>45 | 83 | 20.1 | |
TB history | New cases | 71 | 17.2 |
Retreatment cases | 342 | 82.8 | |
Treatment history | New | 71 | 17.2 |
Relapse | 160 | 38.7 | |
Failure | 132 | 32 | |
Defaulter | 32 | 7.7 | |
Other | 18 | 4.4 | |
Total | 413 | 100 |
3.2 Heteroresistance
3.3 RMP and INH resistance-associated gene mutations
rpoB gene | katG gene | inhA gene | n (%) | ||||||
---|---|---|---|---|---|---|---|---|---|
Failing WT probe | Mutation | Location of codons of WT/mutant/gene | Failing WT probe | Mutation | Location of codons of WT/mutant/gene | Failing WT probe | Mutation | Analyzed nucleic acid position | |
MDR (n = 150) | |||||||||
WT2 and 3 | No | 510513 | WT | MUT1 | S315T1 | No | No | No | 9 (6) |
WT2, 3, and 4 | Unknown | 510520 | WT | MUT1 | S315T1 | No | No | No | 3 (2) |
WT3 and 4 | Unknown | 513519 | WT | MUT1 | S315T1 | No | No | No | 20 (13.3) |
WT3 | Unknown | 514515 | WT | MUT1 | S315T1 | No | No | No | 1 (0.67) |
WT2 | No | 511512 | No | No | No | WT1 | MUT1 | C15T | 1 (0.67) |
WT7 | MUT2A | H526Y | WT | MUT1 | S315T1 | No | No | No | 14 (9.3) |
WT7 | MUT2B | H526D | WT | MUT1 | S315T1 | No | No | No | 5 (3.3) |
WT7 | Unknown | 526 | WT | MUT1 | S315T1 | No | No | No | 14 (9.3) |
WT8 | MUT3 | S531L | WT | MUT1 | S315T1 | No | No | No | 60 (40) |
WT8 | Unknown | 531533 | WT | MUT1 | S315T1 | No | No | No | 6 (4) |
WT8 | MUT3 | S531L | WT | No | Dele, 315 | No | No | No | 11 (7.3) |
WT8 | MUT3 | S531L | No | No | No | WT1 | MUT1 | C15T | 1 (0.67) |
WT8 | MUT3 | S531L | WT | MUT1 | S315T1 | WT1 | MUT1 | C15T | 3 (2) |
WT8 | MUT3 | S531L | WT | MUT2 | S315T2 | No | No | No | 1 (0.67) |
WT8 | Unknown | 531533 | WT | No | Dele, 315 | No | No | No | 1 (0.67) |
RMP-MR (n = 19) | |||||||||
WT7 | MUT2A | H526Y | No | No | No | No | No | No | 4 (21) |
WT7 | MUT2B | H526D | No | No | No | No | No | No | 2 (10.5) |
No | MUT2A | H526Y | No | No | No | No | No | No | 1 (5.3) |
WT8 | MUT3 | S531L | No | No | No | No | No | No | 9 (47.4) |
WT8 | Unknown | 531533 | No | No | No | No | No | No | 3 (15.8) |
INH-MR (n = 26) | |||||||||
No | No | No | WT | MUT1 | S315T1 | No | No | No | 19 (73.1) |
No | No | No | WT | No | Dele, 315 | No | No | No | 4 (15.4) |
No | No | No | No | No | No | WT1 | MUT1 | C15T | 3 (11.5) |
4. Discussion
4.1 Multidrug-resistant tuberculosis
4.2 Heteroresistance

4.3 RMP and INH resistance-associated gene mutations
Acknowledgements
Appendix A. Supplementary data
References
World Health Organization. Global tuberculosis control report. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO; 2011.
- Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.Lancet. 2014; 383: 1572-1579
World Health Organization. Global tuberculosis report. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO; 2012.
- Scaling up interventions to achieve global tuberculosis control: progress and new developments.Lancet. 2012; 379: 1902-1913
- Time for zero deaths from tuberculosis (comment).Lancet. 2011; 378: 1449-1450
World Health Organization. Global tuberculosis report. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO; 2014.
World Health Organization. Global tuberculosis control report. WHO/HTM/TB/2013. Geneva, Switzerland: WHO; 2013.
- Proceedings of the 9th TB-research annual conference (TRAC): 2123 March.in: Hawassa University Conference Center, Hawassa, Ethiopia2014
- Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series]. Drug-resistant tuberculosis.Int J Tuberc Lung Dis. 2009; 13: 1320-1330
- Evolution of drug resistance in M. tuberculosis. Clinical and molecular perspective.Antimicrob Agents Chemother. 2002; 46: 267-274
- Digital PCR to detect and quantify heteroresistance in drug resistant M. tuberculosis.PLoS One. 2013; 8: e57238https://doi.org/10.1371/journal.pone.0057238
- The catalase peroxidase gene and isoniazid resistance of M. tuberculosis.Nature. 1992; 358: 591-593
- Molecular detection of drug resistant tuberculosis by line probe assay. Laboratory manual for resource limited settings.FIND, Geneva, Switzerland2012
- Molecular basis and mechanisms of drug resistance in M. tuberculosis: classical and new drugs.J Antimicrob Chemother. 2011; 66: 1417-1430
- Molecular characteristics of rifampin and isoniazid resistant M. tuberculosis strains from Beijing.China. Chin Med J (Engl). 2007; 120: 814-819
- Mutations in the rpoB gene of multidrug-resistant M. tuberculosis isolates from China.J Clin Microbiol. 2003; 41: 2209-2212
Hain Lifescience. GenoTypeMTBDRplus VER2.0. Instructions for use. IFU-304A-02. Nehren, Germany: Hain Lifescience; 2011.
- Multidrug and extensively drug-resistant tuberculosis.Germany. Emerg Infect Dis. 2008; 14: 1700-1706
- Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in Zahedan, southeastern Iran.Iran Red Crescent Med J. 2012; 14: 53-55
- Transmission of MDR and XDR tuberculosis in Shanghai.China. PLoS One. 2009; 4: e4370
- Epidemiology of tuberculosis in WHO European Region and public health response.Eur Spine J. 2013; 22: 549-555
- The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in M. tuberculosis.Respir Res. 2001; 2: 164-168
- Mechanisms of heteroresistance to isoniazid and rifampin of M. tuberculosis in Tashkent, Uzbekistan.Eur Respir J. 2009; 33: 368-374
- Drug resistance mutations and heteroresistance detected using the GenoTypeMTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India.BMC Infect Dis. 2012; 12: 9
- Drug resistance evolution of a M. tuberculosis strain from a noncompliant patient.J Clin Microbiol. 2005; 43: 3114-3120
- High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010.Emerg Infect Dis. 2012; 18: 29-37
- The GenoTypeMTBDRplus assay for detection of drug resistance in M. tuberculosis in Sweden.APMIS. 2012; 120: 405-409
- Genotypic analysis of isoniazid and rifampicin resistance in drug resistant clinical M. tuberculosis complex isolates in southern Turkey.Jpn J Infect Dis. 2008; 61: 255-260
- Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among M. tuberculosis isolates from Ethiopia.BMC Infect Dis. 2012; 12: 37
- Use of GenoType®MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India.Indian J Med Microbiol. 2013; 31: 230-236
- Performance of the GenoTypeMTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse.J Clin Microbiol. 2013; 51: 1606-1608
- Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan.J Pak Med Assoc. 2012; 62: 767-772
- Application of Genotype MTBDRplus in rapid detection of the M. tuberculosis complex as well as its resistance to isoniazid and rifampin in a high volume laboratory in southern China.Mol Biol Rep. 2011; 38: 2185-2192
- Molecular characterization of multidrug-resistant M. tuberculosis isolated in Nepal.Antimicrob Agents Chemother. 2012; 56: 2831-2836
Article info
Publication history
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy